Recommended Dosage for Malaria Prophylaxis
No standard recommended dosage exists for artesunate in malaria prophylaxis. Artesunate, an artemisinin derivative, is primarily approved for treating severe malaria, not preventing it.[1] The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) do not list it as a prophylactic agent due to limited efficacy data, short half-life requiring frequent dosing, and risk of resistance development.[2][3]
Why Artesunate Isn't Used for Prophylaxis
Artesunate acts rapidly against blood-stage parasites but has poor activity against liver-stage parasites (pre-erythrocytic phase), making it unsuitable alone for preventing infection.[4] Studies in animal models and limited human trials show it reduces parasite burden but fails to provide reliable protection compared to established drugs like atovaquone-proguanil or doxycycline.[5]
Dosing in Treatment vs. Prophylaxis Contexts
For severe malaria treatment in adults, WHO recommends intravenous artesunate at 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy starts.[2] Some experimental prophylaxis regimens tested 2 mg/kg daily or every other day in high-risk settings (e.g., military personnel), but these are not guideline-endorsed and showed breakthrough infections.[6]
Alternatives for Malaria Prophylaxis
| Drug | Adult Dosage | Key Notes |
|------|--------------|-----------|
| Atovaquone-proguanil (Malarone) | 1 tablet daily (250/100 mg) starting 1-2 days before travel | Preferred for short trips; take with food.[3] |
| Doxycycline | 100 mg daily starting 1-2 days before | Long-term option; sun sensitivity risk.[3] |
| Mefloquine | 250 mg weekly starting ≥2 weeks before | Avoid in psychiatric history.[3] |
| Tafenoquine (Arakoda) | 200 mg daily for 3 days loading, then weekly | For ≥9 months; G6PD testing required.[3] |
Potential Risks and Research Gaps
Using artesunate off-label for prophylaxis risks recrudescence, neurotoxicity at high doses, and accelerating artemisinin resistance, as seen in Southeast Asia.[4][7] Ongoing trials (e.g., NCT04112383 on ClinicalTrials.gov) explore artemisinin combinations for prevention, but none support routine use yet.[8]
Sources:
[1] WHO Malaria Treatment Guidelines (2022)
[2] WHO Guidelines for Malaria (2022)
[3] CDC Malaria Prophylaxis (2023)
[4] Lancet Infect Dis review on artemisinins (2018)
[5] Prophylaxis trial in macaques (2017)
[6] Military prophylaxis study (2014)
[7] Resistance review (2017)
[8] ClinicalTrials.gov (ongoing)